Ryvu Therapeutics SA
7 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| RVU120 Rollover Study (NCT06987058) | Ryvu Therapeutics SA | 2025-12-04 |
| MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) (NCT06534437) | Ryvu Therapeutics SA | 2024-12-05 |
| RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (NCT06397313) | Ryvu Therapeutics SA | 2024-09-19 |
| Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (NCT06268574) | Ryvu Therapeutics SA | 2024-01-23 |
| RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors (NCT05052255) | Ryvu Therapeutics SA | 2021-08-13 |
| RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome (NCT04021368) | Ryvu Therapeutics SA | 2019-09-04 |
Track Ryvu Therapeutics SA automatically
Every clearance here is in the API, with alerts when new ones post.